Aim: Determination of changes in serum levels of soluble (s) VEGFR-1 and Tie-2 receptors in colorectal cancer patients following resection in the search for novel tumour markers.

Patients And Methods: Forty-five patients with primary colorectal cancer and 29 normal subjects were recruited. Serum sVEGFR-1 and sTie-2 receptors were assayed using ELISA.

Results: sVEGFR-1 was detectable in 27% (10/37) and 12.5% (1/8) of cancer patients prior to curative and palliative resections, respectively, whilst 65.5% (19/29) of normal controls had detectable sVEGFR-1 levels. sTie-2 receptor levels were significantly raised in patients when compared with normal controls (p=0.0018). Furthermore, sTie-2 receptor levels were significantly higher in patients with metastases than those without (p=0.02). sTie-2 receptors demonstrated a significant drop in patients undergoing both curative (p<0.0001) and palliative resections (p=0.012).

Conclusion: sVEGFR-1 levels were suppressed and sTie-2 receptor levels were raised in colorectal cancer patients. This data supports the potential use of sTie-2 receptor as a tumour marker.

Download full-text PDF

Source

Publication Analysis

Top Keywords

colorectal cancer
12
cancer patients
12
changes serum
8
soluble vegfr-1
8
vegfr-1 tie-2
8
tie-2 receptors
8
receptors colorectal
8
stie-2 receptors
8
normal controls
8
stie-2 receptor
8

Similar Publications

The potential impact of one-carbon metabolism (OCM)-related B vitamins (vitamin B, B, B, and folate) on colorectal cancer survival warrants investigation but research is sparse. This cohort study examined the association between the prediagnostic dietary intakes of OCM-related B vitamins and colorectal cancer survival. A total of 2799 colorectal cancer patients from the Guangdong Colorectal Cancer Cohort, enrolled at baseline in 2010, were followed for mortality outcomes through 2023.

View Article and Find Full Text PDF

Background: Patients with Crohn's disease face an elevated risk of colorectal cancer, in part due to underlying chronic inflammation. Biologic therapy is the mainstay of medical treatment; however, the impact of treatment on colorectal cancer-related outcomes remains unclear.

Objective: To investigate the association between prior exposure to biologic treatment and colorectal cancer-related outcomes in patients with underlying Crohn's disease.

View Article and Find Full Text PDF

Background: One in five sebaceous tumour (ST) patients may have Lynch syndrome (LS), a hereditary cancer predisposition. LS patients benefit from cancer surveillance and prevention programmes and immunotherapy. Whilst universal tumour mismatch repair (MMR) deficiency testing is recommended in colorectal and endometrial cancers to screen for LS, there is no consensus screening strategy for ST, leading to low testing rates and inequity of care.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!